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RUNX2, an essential transcription factor for osteoblast differentiation and bone formation is activated by ERK/MAP kinase-dependent
phosphorylation. However, relationship between these early events and specific epigenetic modifications of chromatin during osteoblast
differentiation have not been previously examined. Here, we explore these relationships using chromatin immunoprecipitation (ChIP) to
detect chromatin modifications in RUNX2-binding regions of Bglap2 and Ibsp. Growth of MC3T3-E1c4 preosteoblast cells in
differentiation conditions rapidly induced Bglap2 and lbsp mRNAs. For both genes, osteogenic stimulation increased chromatin-bound
P-ERK, P-RUNX2, p300, and RNA polymerase II as well as histone H3K9 and H4K5 acetylation. The level of H3K4 di-methylation, another
gene activation-associated histone mark, also increased. In contrast, levels of the gene repressive marks, H3K9 mono-, di-, and tri-
methylation in the same regions were reduced. Inhibition of MAP kinase signaling blocked differentiation-dependent chromatin
modifications and Bglap2 and Ibsp expression. To evaluate the role of RUNX2 phosphorylation in these responses, RUNX2-deficient
C3H10T1/2 cells were transduced with adenovirus encoding wild type or phosphorylation site mutant RUNX2 (RUNX2 S301A/S319A).
Wild type RUNX2, but not the non-phosphorylatedmutant, increasedH3K9 andH4K5 acetylation as well as chromatin-associated P-ERK,
p300, and polymerase II. Thus, RUNX2 phosphorylation is necessary for subsequent epigenetic changes required for osteoblast gene
expression. Taken together, this study reveals a molecular mechanism through which osteogenic genes are controlled by a MAPK and
P-RUNX2-dependent process involving epigenetic modifications of specific promoter regions.
J. Cell. Physiol. 232: 2427–2435, 2017.  2016 Wiley Periodicals, Inc.
Epigenetic modifications of chromatin including histone
acetylation and methylation have major effects on chromatin
structure and gene expression that are critical for the
differentiation of all cell types including osteoblasts. Histone
acetylation, which is considered a hallmark of gene activation, is
catalyzed by histone acetyltransferases (HATs) such as GCN5,
PACAF, P300, and MOF (Grewal and Moazed, 2003).
Conversely, histone deacetylases (HDACs) remove acetyl
groups leading to chromatin condensation and gene repression
(Verdone et al., 2005). Histone methylation has also been
traditionally linked to gene repression, although methylation at
certain sites such as histone H3 at lysine 4, lysine 36, and lysine
79 are associated with gene activation (Wang et al., 2008). Like
histone acetylation, methylation can be reversed by histone
demethylases such as LSD1, LSD2, JMJC1, JMJD1 (A,B,C),
JMJD2 (A,B,C), JARID1 (A,B,C,D), FBXL 2 (Cloos et al., 2008;
Katz et al., 2014).
The MAP kinase pathway is an important mediator of the
response of osteoprogenitor cells to extracellular matrix
composition and stiffness, mechanical loading, hormone,
growth factor, and morphogen stimulation (Xiao et al., 2000,
2002a,b; You et al., 2001; Kapur et al., 2005; Khatiwala et al.,
2009; Li et al., 2012; Greenblatt et al., 2013).
Osteoprogenitor-specific knock out of ERK1/2 (Mapk3/
Mapk1) or overexpression of a dominant-negative MEK1
leads to reduced bone mass and delayed bone development
while overexpression of constitutive-active MEK1 increases
bone formation (Ge et al., 2007; Matsushita et al., 2009).
Upon activation in osteoprogenitor cells, P-ERK translocates
to the nucleus where it binds the RUNX2 transcription
factor on the chromatin of target genes. P-ERK
phosphorylates RUNX2 on specific serine residues that are
necessary for induction of osteoblast-specific transcription
(Ge et al., 2009; Li et al., 2010). The differentiation of
osteoblast from mesenchymal progenitors has been
associated with specific epigenetic modifications including
histone acetylation, methylation, and phosphorylation (Yasui
et al., 2011; Eslaminejad et al., 2013). Recent analysis of
osteoblast differentiation using ChIP-Seq identified gene
clusters associated with transcription factors such as RUNX2
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and C/EBPb and specific histone modifications such as
methylation of H3 lysine 4, acetylation of H3 lysine 9 and H4
lysine 5, and methylation of H3 lysine 27 (Wu et al., 2014;
Meyer et al., 2014a,b). However, the relationship between
these epigenetic changes and the MAPK/RUNX2 pathway
described above has not been previously described.
Here, we explore this relationship by examining
differentiation-related epigenetic changes associated with
RUNX2-binding regions of two important osteoblast-related
genes, Bglap2 and Ibsp. As will be shown, after initiation of
differentiation, P-ERK phosphorylation of RUNX2 initiates a
series of chromatin changes associatedwith RNA polymerase II
recruitment and transcription.
Materials and Methods
Cell culture
Subclone 4 MC3T3-E1 (MC3T3-E1c4) preosteoblast cells were
maintained in growthmedium (GM) containinga-Minimal Essential
Medium (a-MEM; Life Technologies, Inc., Grand Island, NY)
supplemented with 10% fetal bovine serum (FBS; Gibco, Life
Technologies) and 1% penicillin/streptomycin, as described
previously (11). C3H10T1/2 cells were maintained in Dulbecco
Modified Eagle Medium (DMEM, Gibco, Life technologies)
supplemented with 10% fetal bovine serum (FBS; Gibco, Life
technologies) and 1% penicillin/streptomycin. For differentiation
studies, cells were plated at a density of 50,000 cells/cm2 and
cultured in differentiation medium (DM) composed of GM
containing 50mg/ml ascorbic acid.
Antibodies
P-ERK, total ERK, histone H3 dimethyl lysine 4 (H3K4m), histone
H3 mono-, di-, and tri-methyl lysine 9 (H3K9m), histone H3
acetylated at lysine 9 (AcH3K9), histone H4 acetylated at lysine 5
(AcH4K5), and GAPDH antibodies were obtained from Cell
Signaling (Danvers, MA). Pol II and p300/CBP antibodies were
obtained from Santa Cruz Biotechnology (Dallas, TX). Total
RUNX2 antibody was obtained from MBL. Anti-RUNX2-S319-P
antibody was generated in the project laboratory (Ge et al., 2012).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were carried out as
described previously (Li et al., 2010). Briefly, cells were cross-
linked at room temperature with 1% formaldehyde for 10min.
Crude nuclei were then isolated and sheared by sonication.
Chromatin (average size, 500 bp) was pre-cleared by incubation
with protein A/G agarose beads (Santa-Cruz Biotechnology)
followed by incubation with primary antibodies against P-ERK,
RUNX2, RUNX2-S319-P, Pol II, P300, H3K4m, H3K9m, AcH3K9,
and AcH4K5, respectively, and precipitated with A/G agarose
beads. Input DNA andDNA fromChIP samples weremeasured by
PCR (35 cycles) or by quantitative real-time PCR as previously
described (Li et al., 2010). These latter measurements used
previously described Taqman probes flanking OSE2a and OSE2b
RUNX2 binding sites in Bglap2 or the transcribed region of Bglap2,
a RUNX2—binding site in the proximal Ibsp promoter or distal site
in Ibsp that is devoid of Runx2 binding activity.
Quantitation of mRNA
Total RNA was extracted from cells using TRIzol reagent
(Invitrogen, Carlsbad, CA) and cleaned with an RNeasy Mini Kit
(Qiagen, Valencia, CA). Single strand cDNA was synthesized using
Taqman reverse transcriptase (Applied Biosystems, Carlsbad,
CA). Quantitative real-time polymerase chain reaction (PCR)
measurement of Bglap2, Ibsp, and GapdhmRNAwas carried out as
described previously (22) using predeveloped Taqman probes and
an ABI PRISM 7700 sequence detector (Applied Biosystems).
mRNA expression was normalized to Gapdh mRNA.
Western blot
Cells were harvested in lysis RIPA buffer (10Mm Tris, Ph7.5, 5mM
EDTA, 1% Triton X-100, 150mM NaCI, 0.1% SDS, PMSF,
1 proteinase inhibitor cocktail, Sigma, St. Louis, MO). Protein
samples were separated by SDS–PAGE using 4–20% Novex Tris–
Glycine gels (Life technologies). After transfer to nitrocellulose
membranes, samples were incubated with total RUNX2 (1:500
dilution), phospho-ERK (1:1000 dillution), total ERK (1:1000
dilution), or GAPDH (1:2000 dilution) antibodies, respectively,
overnight at 4°C. A secondary antibody of sheep anti-mouse
conjugated with horseradish perioxidse (GE Healthcare, UK) was
used at 1:10000 dilution. Protein expression was detected by ECL
(Amersham, UK).
Statistical analysis
The results are presented asmean SE, with n¼ 3 per group for all
comparisons. Statistical analysis was determined using a one-way
ANOVA followed by Tukey’s multiple-comparison test.
Results
Chromatin changes accompanying induction of
osteoblast gene expression
Induction of osteoblast differentiation is accompanied by
gradual (within 1–3 days) activation of ERK/MAP kinase activity.
P-ERK translocates to the nucleus where it binds and
phosphorylates RUNX2 at several sites including S319. These
changes are followed by induction of osteoblast marker genes
such as Bglap2 and Ibsp (Li et al., 2010; Ge et al., 2012). An
example of this mRNA induction is shown in Figure 1, where
MC3T3-E1c4 cells were maintained in growth (GM) or
differentiation medium (DM) for 3, 6, or 9 days before RNA
isolation. Induction of both mRNAs was detected by 3 days
with levels continuing to increase through the 9 day time point.
To examine chromatin changes associated with Bglap2
and Ibsp mRNA induction, ChIP analysis was conducted
using previously characterized RUNX2-binding regions of
these two genes (shown in Fig. 2A) (Ducy and Karsenty,
1995; Roca et al., 2005). Bglap2 contains 2 RUNX2-binding
enhancers in the proximal promoter at 130 bp (OSE2a)
and at 605 bp (OSE2b), respectively. An additional primer
pair detected binding to the transcribed region of Bglap2 at
þ400 bp (TSR). Primers were also designed to detect
interactions with two regions of Ibsp, a region in the first
200 bp of the proximal promoter (Prox) containing two
functional RUNX2-specific enhancers and a second non-
functional cryptic RUNX2 consensus binding site at
1300 bp (Dist). This later site does not bind RUNX2 in
ChIP assays, lacks enhancer activity, and therefore, serves as
a negative control (Roca et al., 2005). Each site is sufficiently
separated from adjacent sites such that it is not
immunoprecipitated in the same chromatin fragment during
ChIP analysis, thereby allowing each site to be analyzed
separately (Li et al., 2010). ChIP analysis was conducted
using cells grown for up to 6 days in GM or DM. Although
time course studies revealed that early P-ERK binding,
RUNX2 phosphorylation and epigenetic changes in
chromatin could be detected after 2–3 days in DM (Suppl.
Fig. S1), the 6 day time point was selected for detailed
analysis because more robust epigenetic changes and strong
induction of Bglap2 and Ibsp mRNAs were seen by this time.
Figure 2B shows semi-quantitative PCR analysis of ChIP
samples while Figure 2C provides more quantitative data
using real-time PCR detection of ChIP DNA. Consistent
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with our previous report (Li et al., 2010), growth in DM
stimulated the association of P-ERK with RUNX2-binding
regions of Bglap2 (OSE2a, OSE2b) and Ibsp (BSPprox). In
contrast, P-ERK did not bind to the transcribed region of
Bglap2 (TSR) or distal region of Ibsp since these regions do
not bind RUNX2, which is necessary for chromatin docking
of P-ERK (Li et al., 2010). Although the differentiation
condition did not significantly affect total bound RUNX2,
chromatin-associated P-RUNX2, measured with an
antibody that preferentially detects RUNX2-S319-P, was
dramatically increased at all three sites (OSE2a, OSE2b, and
Prox) as would be expected if RUNX2 were being
phosphorylated by the associated P-ERK. Coincident with
these changes was the association of the HAT, p300, with
chromatin, changes in histone acetylation and methylation,
and increased binding of RNA polymerase II (Pol II). The
histone marks selected for analysis were acetylation at
histone H3 lysine 9 and H4 lysine 5 (AcH3K9 and AcH4K5),
which are both associated with gene activation, mono-, di-,
or tri-methylation at H3 lysine 9 (detected with pan-H3K9m
antibody) associated with repression and di-methylation at
H3 lysine 4 (H4K5m) associated with gene activation
(Grewal and Moazed, 2003). Levels of AcH3K9 and AcH4K5
were elevated in OSE2a and OSE2b regions of Bglap2 and
the proximal region of Ibsp (BSPprox). In addition, the
activation-associated methylation mark, H4K5m, was
increased while a consistent decline in the repressive mark,
H3K9m, was observed at all three sites. Because levels of all
marks were at low to undetectable levels in the TSR of
Bglap2 and the distal region of Ibsp (Fig. 2B), these
chromatin regions were not used in subsequent analysis.
As noted above, the differentiation condition increased
association of p300 with RUNX2-binding regions of Bglap2 and
Ibsp, which may explain the observed increases in histone
acetylation. In an attempt to explain the observed increase in
H3K4 dimethylation, we also measured chromatin levels of the
histone demethylase, LSD2, which preferentially removes
mono and dimethly groups from H3K4m (Katz et al., 2014).
However, we did not observe any LSD2 binding changes
betweenDM andGM suggesting that the observedmethylation
changes in H3K4m could not be explained by regulation of this
demethylase.
MAP kinase activity is necessary for
differentiation-dependent chromatin modifications
Previous studies established that ERK must be in its activated,
phosphorylated form to bind RUNX2 on chromatin (Li et al.,
2010, 2012). However, the role of MAPK signaling in the
differentiation-dependent chromatin changes described above
has not been examined. To address this issue, cells were grown
in DM for 6 days and then treated with the MAPK inhibitor,
U0126, for 12 h. Previous work established this treatment time
as being sufficient to block MAPK signaling and osteoblast gene
expression while avoiding toxicity associated with chronic
inhibitor exposure (Xiao et al., 2002a). This is confirmed in the
results shown in Figure 3A–Cwhere U0126 treatment blocked
MAPK activity (ERK phosphorylation) as well as Ibsp and Bglap2
mRNA induction. Inhibitor treatment also totally or partially
reverse all the differentiation-related chromatin changes
described in Figure 1. Thus, increases in chromatin-associated
P-ERK, P-RUNX2, Pol II, p300, and the gene activation-
associated histone marks H3K4m, AcH3K9, and AcH4K4 all
returned to control levels in U0126-treated samples regardless
of the chromatin site examined (Fig. 3D–F). The differentiation-
dependent reduction in the inhibitory chromatin marks
detected with H3K9m antibody was also partially reversed by
inhibitor treatment although this reversal was not complete
and results varied between chromatin sites (compare H3K9m
result for OSE2a-Panel D, with Panels E and F). Taken together,
these results indicate that MAPK activity is required for
subsequent differentiation-related chromatin changes and gene
expression.
RUNX2 phosphorylation is necessary for
differentiation-related changes in chromatin occupancy
and epigenetic marks
A final series of experiments evaluated the role of RUNX2
phosphorylation in differentiation-related chromatin changes.
Fig. 1. Time course of Bglap2 and IbspmRNA expression during osteoblast differentiation. Preosteoblast MC3T3-E1 subclone four cells were
cultured in growth medium (GM) or differentiation medium (DM) for the times indicated. Total RNA was isolated and Bglap2 and IbspmRNA
levels measured by qRT-PCR.
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Fig. 2. Differentiation-dependent epigenetic changes associated with Runx2-binding regions in the proximal promoter regions of Bglap2 and
Ibsp. (A) Schematic of proximal promoters of Bglap2 and Ibsp showing regions amplified during ChIP analysis. OSE2a and OSE2b are
functional Runx2 binding sites in Bglap2. A control region (Ct) in the transcribed region of Bglap2 is also shown. Ibsp contains distal (Dist) and
proximal (Prox) consensus Runx2 binding sites, but only the proximal site is functional. (B and C) ChIP analysis using different amplified
regions of Bglap2 and Ibsp shown in (A). MC3T3-E1c4 cells were cultured in growth (GM) or differentiation medium (DM) for 6 days. Isolated
chromatin was immunoprecipitated with the indicated antibodies to determine the chromatin association of P-ERK, RUNX2, P-RUNX2, RNA
polymerase II (Pol II), histone acetylase p300 (P300), histone H3 methylation at lysine 4 (H3K4m) and lysine 9 (H3K9m), histone H3
acetylation at lysine 9 (AcH3K9) and histone H4 acetylation at lysine 5 (AcH4K5). (B) Gel image of semi-quantitative PCR results. (C)
Quantitative PCR analysis of ChIP results using TaqMan probes for OSE2a and OSE2b regions of Bglap2 and the Prox region of Ibsp.
Significant differences between DM and GM samples: P 0.05 (a), P 0.01 (b), n¼ 3.
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Fig. 3. MAP kinase activity is required for induction of osteoblast gene expression and chromatin-associated epigenetic changes. MC3T3-
E1c4 cells were cultured in GM and DM for 6days and then treated with 20mg/ml U0126 for 12h. Cells were subsequently harvested for
measurement of P-ERK and total ERK (A), Bglap2 and IbspmRNA (B and C) and ChIP analysis using the indicated antibodies (D–F). Statistics:
Comparisons were conducted between cells grown in DM without UO126 and in DM with UO126. (a) P 0.05, (b) P 0.01, n¼ 3.
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Fig. 4. Runx2 and Runx2 S301/S319 phosphorylation are required for induction of osteoblast gene expression and chromatin-associated
epigenetic changes. C3H10T1/2 cells were transduced with control adenovirus (LacZ), virus expressing wild type RUNX2 (Runx2 WT) or
RUNX2 containing S301A, S319A mutations (Runx2 SA). After 2 days, cells were switched to GM or DM and cultured for an additional 6 days
before analysis of gene expression (A). RUNX2 protein levels were measured in cells grown in DM for 2 or 8days (B) while ChIP analysis used
cells grown in DM for 6days (C–E). Statistics: Comparisons were conducted between groups indicated by horizontal bars. (a) P 0.05, (b)
P 0.01, n¼ 3.
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C3H10T1/2 cells, which have low endogenous RUNX2 levels,
were transduced with adenovirus vectors expressing LacZ,
wild type RUNX2 (RUNX2 WT), or a phosphorylation-
deficient mutant containing serine to alanine mutations at S301
and S319 (RUNX2 SA). As previously shown, phosphorylation
at these sites is necessary for MAPK-dependent RUNX2
transcriptional activity (Ge et al., 2009; Ge et al., 2016). This is
confirmed by the result shown in Figure 4A where wild type
RUNX2 strongly stimulated Bglap2 and IbspmRNAswhen cells
were grown in DM while the phosphorylation site mutant
expressed at equivalent levels was much less active (Fig. 4A
and B).
ChIP assays were next used to assess effects of RUNX2
and RUNX2 phosphorylation on recruitment of factors to
chromatin and epigenetic marks (Fig. 4C–E). Equivalent
binding of wild type or mutant RUNX2 was detected at
OSE2a, OSE2b, and BSPprox chromatin sites. However,
dramatic differences in levels of other chromatin-associated
factors were observed. In agreement with our previous
report that RUNX2 is necessary for docking of P-ERK on
chromatin, cells expressing wild type RUNX2 showed a
dramatic increase in chromatin-associated P-ERK when
compared with LacZ controls (Li et al., 2010). However,
P-ERK binding was reduced in cells expressing RUNX2 SA.
As expected, the ChIP signal with the anti-RUNX2-S319-P
antibody (P-Runx2) was greatly reduced in cells transduced
with the RUNX2 SA mutant. Consistent with its enhanced
transcriptional activity, wild type RUNX2 increased
chromatin-associated p300, the gene activation-associated
histone marks, H3K4m, AcH3K9, and AcH4K5, as well as Pol
II while the RUNX2 SA mutant was significantly less active.
Paradoxically, the inhibitory marks detected by the pan
H3K9m antibody were actually increased in both wild type
and RUNX SA groups. Nevertheless, the general conclusion
from these studies is that RUNX2 must be phosphorylated at
S301 and S319 to recruit accessory factors to chromatin
leading to epigenetic changes necessary for transcriptional
activation.
Discussion
This study examined the relationship between RUNX2
phosphorylation and differentiation-dependent chromatin
modifications of the proximal RUNX2-binding regions of
Bglap2 and Ibsp. Initiation of differentiation was associated with
translocation of P-ERK to the nucleus where it associated with
and phosphorylated RUNX2 previously bound to specific
enhancer-containing chromatin regions. These events were
required for subsequent recruitment of p300/CBP to
chromatin, increases in gene activation-associated epigenetic
histone marks (H3K4m, AcH3K9, and AcH4K5), reduction in
the repressive histone mark, H3K9m, RNA polymerase II
recruitment, and transcription. These findings support the
model shown in Figure 5 where RUNX2 phosphorylation plays
a pivotal role in recruiting chromatin-modifying factors to gene
enhancers thereby allowing the epigenetic changes necessary
for transcription and osteoblast differentiation.
Results of the present study are reminiscent of previous
work from this laboratory that examined the role of RUNX2
phosphorylation in the response of osteoblasts and bone to
mechanical loading (Li et al., 2012). Both exposure of
preosteoblasts to fluid flow shear stress (FFSS) and ulnar
loading of mice were shown to increase MAPK signaling and
RUNX2 S319 phosphorylation. Similar to the present study,
the ability of FFSS to stimulate osteoblast gene expression
required MAPK activation and RUNX2 S301, S319
phosphorylation. Furthermore, these phosphorylation events
were shown to be required for overall increases in histone
acetylation although the specific histone acetylation marks
involved were not identified nor was histone methylation
examined.
As suggested in the present study, phosphorylation of
RUNX2 may affect its ability to bind P-ERK and p300/CBP in
that chromatin binding of these factors was dramatically
reduced in cells treated with a MAPK inhibitor or transfected
with a phosphorylation-deficient RUNX2 mutant (RUNX2
SA). Although a direct association of these factors with
RUNX2 cannot be inferred from ChIP analysis, we previously
obtained evidence using immunoprecipitation that ERK directly
binds RUNX2 and identified a consensus MAPK-binding D site
between amino acids 201 and 215 in the runt domain that was
necessary for this binding (Ge et al., 2009). Interestingly, in that
study mutation of S301 and S319 phosphorylation sites in
RUNX2 (RUNX2 SA) did not affect its ability to bind ERKwhile
in the present study, chromatin binding of P-ERK was reduced
in cells transfected with RUNX2 SA versus wild type RUNX2
Fig. 5. Model showing differentiation-dependent changes in
chromatin structure induced by ERK-dependent RUNX2
phosphorylation. In undifferentiated preosteoblast cells, RUNX2 is
already bound to relevant enhancer sites on chromatin together
with histone H3 methylated at lysine 9 (H3K9m). Levels of histone
H3 acetylation at lysine 9 and H4 acetylation at lysine 5 remain low
consistent with the condensed state of chromatin. After induction of
differentiation, P-ERK translocates to the nucleus where it binds and
phosphorylates RUNX2 at S301 and S319. Phosphorylated RUNX2
facilitates binding of the histone acetyltransferase, p300, to
chromatin leading to acetylation of H3 at lysine 9 and H4 at lysine 5.
In addition, an as yet unidentified methyltransferase is also recruited
resulting in methylation of histone H3 at lysine 4. Together, these
epigenetic changes stimulate chromatin decondensation, increased
RNA polymerase II recruitment and transcription of osteoblast
genes.
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(Fig. 4). Since we previously establish that ERK does not bind
the chromatin regions studied in the absence of RUNX2 (Li
et al., 2010), these results may reflect unique aspects of the in
vivo chromatin environment that require intact RUNX2
phosphorylation sites for optimal P-ERK binding. There is also
evidence from other laboratories that RUNX2
phosphorylationmediated by either p38 or ERKMAP kinases is
important for complex formation with p300/CBP and Smads
(Afzal et al., 2005; Greenblatt et al., 2010). In the former study,
p38 MAPK-mediated phosphorylation of RUNX2 at several
serine residues including the S319 ERK/MAPK site analyzed in
the present study was shown to be necessary for binding to
p300/CBP in immunoprecipitation assays. In the latter study,
treatment with a MAP kinase inhibitor blocked the co-
immunoprecipitation of RUNX2 with Smad1.
We do not currently know the full range of factors that are
recruited to chromatin by P-RUNX2. From our analysis, it is
clear that RUNX2 phosphorylation stimulates histone
acetylation (AcH3K9, AcH4K5) and the activation-associated
methylation mark, dimethyl H3K4, while suppressing mono, di,
and tri-methyl H3K9. However, it is not known whether the
observed changes in acetylation are explained by the
recruitment of p300/CBP to chromatin. In fact, the ability of
p300/CBP to stimulate RUNX2-dependent transcription of the
osteocalcin gene was previously reported to not require HAT
activity (Sierra et al., 2003), although HAT activity of p300/CBP
was required for PTH induction of Mmp13 (Boumah et al.,
2009). Alternately, results could be explained by suppression of
HDACs, some of which are known to associate with RUNX2
(Jensen et al., 2008; McGee-Lawrence andWestendorf, 2011).
Similarly, the nuclear factors responsible for the observed
differentiation-related increases in H3K4 dimethylation and
inhibition of H3K9 mono, di, and tri-methylation remain to be
described. Because of its specificity for removingmethyl groups
from histone H3K4, chromatin levels of the histone
demethylase, LSD2, were examined, but no differentiation-
related changes were observed (Fig. 2). Although not examined
in the present study, the demethylases KDM4B and KDM6B
were previously shown to be required for osteogenic
differentiation of human MSC (Ye et al., 2012). KDM4B
selectively demethylates trimethyl H3K9 so it could be
involved in the differentiation-related reduction of this histone
mark. KDM6B demethylates trimethyl H3K27, which was not
examined in our study. Clearly, further work will be required
to define the breadth of nuclear factors recruited to chromatin
by phosphorylated RUNX2 and relate them to the epigenetic
changes observed.
Because theChIP analysis in the present study was restricted
to proximal regions of Bglap2 and Ibsp known to contain
functional RUNX2-binding enhancers, it might be questioned
whether our conclusions are relevant to understanding the
role of RUNX2 phosphorylation at a genomic level. While a
definitive answer to this question would require genomic
analysis of P-RUNX2 distribution using ChIP-Seq, some insight
into the broader relevance of our work can be gleaned by
consideration of recent ChIP-Seq studies on total RUNX2
distribution that were conducted using differentiated
osteoblasts (Wu et al., 2014; Meyer et al., 2014a). In both
studies, chromatin-associated RUNX2 was broadly distributed
throughout the genome with about 30% of RUNX2 occupancy
in the promoter regions of putative target genes and 70% of
RUNX2 located in non-promoter regions including intron,
exon, and intergenic regions. Most interestingly, RUNX2
binding sites were frequently in chromatin regions containing
methylated histone H3K4 as well as acetylated histones H3K9
and H4K5, the same activating histone marks that were
associatedwith and shown to require RUNX2 phosphorylation
in the present study (Meyer et al., 2014a). Because ChIP-Seq
analysis was conducted using differentiated osteoblasts, it is
likely that much of the chromatin-associated RUNX2 detected
was in the phosphorylated form. It can, therefore, be inferred
that RUNX2 phosphorylation at S301 and S319 likely has broad
effects through out the genome leading to local increases in
activating histone marks, chromatin decondensation and gene
expression.
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